QS Batterymarch Financial Management’s Anika Therapeutics ANIK Stock Holding History

QS Batterymarch Financial Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$2.47M	Sell	67,453 -60,084	-47%	-$2.6M	0.07%	373
2014 Q2	$5.91M	Sell	127,537 -10,810	-8%	-$481K	0.15%	223
2014 Q1	$5.69M	Sell	138,347 -5,200	-4%	-$193K	0.12%	256
2013 Q4	$5.48M	Buy	143,547 +104,247	+265%	+$3.22M	0.12%	284
2013 Q3	$939K	Hold	39,300	–	–	0.02%	633
2013 Q2	$669K	Buy	+39,300	New	+$567K	0.01%	682

Other funds holding ANIK

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

QS Batterymarch Financial Management's ANIK Position: Q3 2014 in Review

QS Batterymarch Financial Management reduced its Anika Therapeutics (ANIK) stake by 47% in Q3 2014, selling an estimated $2.6M and leaving 67,453 shares worth $2.47M. The position accounts for 0.07% of the portfolio, ranked #373.

QS Batterymarch Financial Management first reported a position in ANIK in Q2 2013 and has held it in 6 quarters since. The position peaked at $5.91M in Q2 2014. 153 funds tracked by Wall St. Rank hold ANIK as of Q3 2014.

QS Batterymarch Financial Management held 67,453 shares of Anika Therapeutics worth $2.47M as of Q3 2014.
QS Batterymarch Financial Management sold 60,084 Anika Therapeutics shares in Q3 2014, an estimated $2.6M.
Anika Therapeutics made up 0.07% of QS Batterymarch Financial Management's portfolio in Q3 2014, its #373 holding.
QS Batterymarch Financial Management first reported a position in Anika Therapeutics in Q2 2013 and has held it in 6 quarters since.
QS Batterymarch Financial Management's Anika Therapeutics position peaked at $5.91M in Q2 2014.
153 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2014.

Based on QS Batterymarch Financial Management's 13F filing for Q3 2014, filed 14 Nov 2014.